

## ASX Market Announcement

12 August 2024

Dear Shareholder

### Non-renounceable Entitlement Offer

On behalf of the Board of Genetic Technologies Limited ACN 009 212 328 (**Company**), I invite Eligible Shareholders to participate in the Company's Entitlement Offer of 2 New Shares for every 3 Shares held at the Record Date of 7 August 2024 at an Issue Price of 4 cents per New Share, plus 1 New Option for every New Share issued under the Offers (expiring two years from its issue date and with an exercise price of 4 cents (\$0.04)) - to raise a minimum of \$2 million (**Minimum Subscription Amount**) and up to maximum of approximately \$3.88 million (**Maximum Subscription Amount**) (before expenses).

Eligible Shareholders may also subscribe for Additional Securities beyond their Entitlement (on the basis that some existing shareholders will either be ineligible or may fail to fully take up their Entitlement). This ability to apply for Additional Securities is restricted only to Eligible Shareholders who also subscribe for their full Entitlement, is determined at the discretion of the Board and is referred to as a 'Top-Up Facility'. The Directors have also reserved the right for up to 3 months after the close of the Offer to place any remaining Shortfall, at the Board's discretion, but at a price no less than the Issue Price.

Your Directors have committed to partially underwriting the Offers by applying a total of \$500,000 towards the Minimum Subscription Amount, in reduction of their existing Secured Loans to the Company. Please refer to section 2.4 of the Prospectus for further details.

The Offers may be summarised as follows:

- Eligible Shareholders holding Shares may subscribe under the Entitlement Offer for 2 New Shares for every 3 Shares held as at the Record Date of 7.00 pm on 7 August 2024, which Entitlement Offer includes the issue to the subscribers of 1 New Option for every New Share issued under the Entitlement Offer (including 1 New Option for every New Share issued under any Shortfall) (**Offer**).
- The issue price for New Shares is \$0.04 (4 cents) per New Share.
- There is a minimum subscription to be raised under this Prospectus before the Entitlement Offer can close, namely the \$2 million (**Minimum Subscription Amount**).
- Eligible Shareholders may also subscribe for Additional Shares (and corresponding New Options) beyond their Entitlement on the basis that some other existing Shareholders will be either ineligible or may fail to fully take up their Entitlement (**Top-Up Offer**). This Top-Up Offer to apply for Additional Securities is restricted only to Eligible Shareholders.
- If there remains any Shortfall after allocation of Entitlements to Eligible Shareholders under the Entitlement Offer and Top-Up Offer and the application of the \$500,000 in reduction of the Secured Loans, the Directors also reserve the right for up to 3 months after the close of the Entitlement Offer to place any Shortfall at the Board's discretion under this Prospectus but at a price no less than the Issue Price (**Shortfall Offer**).

**This letter is to notify you that the Entitlement Offer is now open and to provide you with instructions on how to obtain a copy of the Offer Booklet and your personalised Entitlement and Acceptance Form.**

**How to obtain a copy of the Prospectus and your personalised Entitlement and Acceptance Form:**

**1. ONLINE:** To accept the offer and subscribe for New Shares and Options under the Entitlement Offer, Eligible Shareholders can view a copy of the Prospectus and their personalised Entitlement and Acceptance Form online at [www.computersharecas.com.au/GTGOffer](http://www.computersharecas.com.au/GTGOffer). To access the website you will need your SRN or HIN, which is displayed at the top of this letter.

**2. PAPER:** You can request a paper copy of the Prospectus and personalised Entitlement and Acceptance Form by contacting the Company via the Offer Information Line on (03) 8412 7000 (within Australia) or +613 8412 7000 (outside Australia) or via email at [investors@genetype.com](mailto:investors@genetype.com).

**Indicative Timetable**

<b>Event</b>	<b>Date</b>
<b><u>Record Date</u></b> to determine Entitlements under the Entitlement Offer	Wednesday, 7 August 2024
Prospectus (including Entitlement & Acceptance Form) despatched.	Monday, 12 August 2024
<b><u>Opening Date</u></b>	Monday, 12 August 2024
<b><u>Closing Date</u></b> for acceptances under the Entitlement Offer and Top-Up Offer	Monday 2 September 2024
<b><u>Results of the Offer and Shortfall</u></b> (if any) announced to the ASX	Monday, 9 September 2024
<b><u>Issue of the New Shares and New Options</u></b>	Monday, 9 September 2024
<b><u>Trading</u></b> (T+2) of New Shares expected to commence	Tuesday, 10 September 2024
Holding Statements sent to subscribers under the Entitlement Offer	Wednesday, 11 September 2024

*\* The above dates are indicative only and subject to change. The Company reserves the right, subject to the Corporations Act and the Listing Rules, to extend these dates without prior notice including extending the last date for receipt of the Applications, or to delay or withdraw the Offer at any time without prior notice. If withdrawn, all Application Monies for New Shares which have not been issued will be refunded (without interest) as soon as practicable.*

The funds from the Offer are to be applied to working capital and to fund the Company's transition to a leaner capital light operations structure (as announced to the ASX market on 26 July 2024). Further detail on the application of funds raised is found at section **Error! Reference source not found.** of this Prospectus.

As a Board, we appreciate the support of our existing Shareholders and we have been mindful of providing existing Shareholders this opportunity to maintain (or possibly increase) their relative investment in the Company.

**Further Information**

If you have any queries concerning your Entitlement, please contact the Company via the Offer Information Line on (03) 8412 7000 (within Australia) or +613 8412 7000 (outside Australia) or via email at [investors@genotype.com](mailto:investors@genotype.com).

We look forward to your participation in the Offers.

Yours sincerely,

A handwritten signature in blue ink, appearing to read 'P. Rubinstein'.

Mr Peter Rubinstein  
Chair  
Genetic Technologies Limited